Argentina’s $14B Pharma Market: IP Traps, Deregulation Windfalls, and the Exact Strategy to Profit from Both
Argentina’s pharmaceutical market is a $7.3 billion commercial arena projected to reach $14.2 billion by 2030 — and it is […]
November 2025
The $400B Generic Drug Playbook: How Lipitor, Plavix, and Gleevec Were Won
The three most consequential generic drug launches in pharmaceutical history share almost nothing in surface mechanics. One ended in a
The $400B Generic Drug Playbook: How Lipitor, Plavix, and Gleevec Were Won Read Post »
Generic Drugs for Low-Income Markets: The Formulation, IP, and Regulatory Playbook
The global generic drug industry saves the U.S. healthcare system roughly $2.9 trillion per decade. In high-income markets, this model
Generic Drugs for Low-Income Markets: The Formulation, IP, and Regulatory Playbook Read Post »
The $500B Biologic Patent Fortress: How Humira, Enbrel, and Keytruda Built Monopolies That Last Decades
Biologic drugs generate more revenue per product than any other class of medicine. They also carry more patents, attract more
How Paragraph IV Patent Challenges Actually Work: The $200B Generic Drug Playbook
The Hatch-Waxman Act created the modern generic drug industry in 1984. Forty years later, the Paragraph IV certification it established
How Paragraph IV Patent Challenges Actually Work: The $200B Generic Drug Playbook Read Post »
Drug Patents vs. PTAB:Who Actually Wins?
The Patent Trial and Appeal Board has quietly become the most consequential forum in pharmaceutical IP. This is the definitive
Drug Patents vs. PTAB:Who Actually Wins? Read Post »
The CIP Trap: How Continuation-in-Part Applications Can Make or Break a Drug Patent Portfolio
Every year, pharmaceutical companies collectively forfeit billions in potential patent term by misusing one of the most misunderstood tools in
The $75M Bet: Building a Branded Analgesic from Two Generic Pills
Two off-patent molecules. A single tablet. A decade of exclusivity and margins that rival any branded biologic. That is the
The $75M Bet: Building a Branded Analgesic from Two Generic Pills Read Post »
The Hidden $19 Billion Signal: How Pharma’s Best Intelligence Teams Spot Formulation Switches Before They Happen
The active pharmaceutical ingredient gets all the attention. Patent cliffs, IND filings, NDA approvals, blockbuster valuations — the API is
